Announcements Trials

Browse Landscape

Phase

Status

Withdrawn 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 36 Tumor-Agnostic 5 Thoracic 3 Head & Neck 3 Other solid neoplasm 2 Gastrointestinal 2 Sarcoma 1 Gynecologic 1 CNS 1 Breast 1

Conditions

Interventions

Radiotherapy 144 Doxorubicin 112 Temozolomide 110 Cyclophosphamide 110 Filgrastim 79 Ifosfamide 70 Imatinib Mesylate 69 Etoposide 69 Bevacizumab 55 Vincristine 51 Gemcitabine 50 Peripheral Blood Stem Cell Transplantation 47 Irinotecan 43 Methotrexate 39 Cisplatin 36 Carboplatin 36 Radiation 35 fludarabine phosphate 34 Busulfan 34 pazopanib 32 Sirolimus 30 Melphalan 30 Trabectedin 29 Docetaxel 27 Chemotherapy, Adjuvant 27 Cyclosporine 25 Carmustine 25 sargramostim 24 Surgical Procedures, Operative 23 Sunitinib 23

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × cabazitaxel × Sarcoma × Clear all

NCT01913652 2021-09-14

Ph II Cabazitaxel DD Liposarcoma

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2 Completed

Liposarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡